Corpus Intelligence IC Memo — CENTRO COMPRENSIVO DE CANCER 2026-04-26 09:54 UTC
IC Memo — CENTRO COMPRENSIVO DE CANCER
Investment Committee Memorandum | PR | 48 beds | Grade D | EBITDA uplift $1.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CENTRO COMPRENSIVO DE CANCER

CCN 400135 | SAN JUAN MUNICIPIO, PR | 48 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

CENTRO COMPRENSIVO DE CANCER is a 48-bed safety-net/medicaid heavy in SAN JUAN MUNICIPIO, PR with $20.4M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 0.6% Medicare, 39.2% Medicaid, and 60.2% commercial.

Thesis: Turnaround. Our ML models identify $1.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -123.0% (+736bps).

Net Revenue HCRIS$20.4M
Current EBITDA COMPUTED$-26.6M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS39.8%
Revenue / Bed COMPUTED$425K
Net-to-Gross HCRIS31.9%
Distress Probability ML59.2%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
14
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -100.0% places it below the state median. Among 14 size-comparable peers (24-96 beds), the median margin is -15.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (24-96), prioritizing same-state peers. 14 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CENTRO COMPRENSIVO DE CANCER (Target)PR48$20.4M-100.0%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL MENONITA HUMACAOPR73$53.1M31.3%
HOSPITAL METRO HATO REY INC.PR84$34.2M-18.8%
HOSP. METROPOLITANO DE SAN GERPR63$28.5M-8.2%
CARIBBEAN MEDICAL CENTERPR44$24.8M-0.6%
HOSPITAL METROPOLITANO TITO MAPR67$24.3M-17.0%
ENCOMPASS HEALTH REHABILITATIOPR42$17.4M9.9%
HOSPITAL I GONZALEZ MARTINEZPR40$15.2M-50.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$428K+210bp18mo
Cost to Collect4.5%2.5%$408K+200bp12mo
Denial Rate Reduction12.0%6.5%$404K+198bp12mo
A/R Days Reduction5200.0%3800.0%$248K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$428K
Cost to Collect
$408K
Denial Rate Reduction
$404K
A/R Days Reduction
$248K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.5M
Current EBITDA$-26.6M
+ RCM Uplift+$1.5M
Pro Forma EBITDA$-25.1M
Current Margin-100.0%
Pro Forma Margin-123.0%
WC Released (1x)$782K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-40.9M$-160.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-40.9M$-189.7M0.00x-100.0%
Bull Case9.0x11.0x$-36.8M$-198.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-36.8M$-226.8M0.00x-100.0%
Bear Case11.0x10.0x$-45.0M$-154.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-45.0M$-184.6M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (39.2%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 59.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 14 hospitals with 24-96 beds
  • Same-state prioritization (n=15)
  • Comp margins: P25=-42.6% / P50=-15.1% / P75=-0.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.